KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma
- 17 July 2014
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (3) , 487-495
Abstract
Purpose Exportin-1 (XPO1, CRM1) mediates the nuclear export of several key growth regulatory and tumor suppressor proteins. Cancer cells often overexpress XPO1 resulting in cytoplasmic mislocalization and aberrant activity of its target proteins. Orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to and inhibit the function of XPO1 have been recently developed. The aim of this study was to investigate the efficacy of the clinical staged, orally available, SINE compound, KPT-330 in hepatocellular carcinoma (HCC). Methods In silico, meta-analysis showed that XPO1 is overexpressed in HCC. Six HCC cell lines were treated with KPT-330, and cell proliferation and expression of cell growth regulators were examined by cell proliferation assays and Western blot analysis, respectively. The in vivo anti-cancer activity of KPT-330 was examined in a HCC xenograft murine model. Results KPT-330 reduced the viability of HCC cell lines in vitro and this anti-proliferative effect was associated with cell cycle arrest and induction of apoptosis. The expression of the pro-apoptotic protein PUMA was markedly up-regulated by KPT-330. In addition, SINE treatment increased the expression of the tumor suppressor proteins p53 and p27, while it reduced the expression of HCC promoting proteins, c-Myc and c-Met. XPO1 levels itself were also down-regulated following KPT-330 treatment. Finally, a HCC xenograft murine model showed that treatment of mice with oral KPT-330 significantly inhibited tumor growth with little evidence of toxicity. Conclusion Our results suggest that SINE compounds, such as KPT-330, are promising novel drugs for the targeted therapy of HCC.Keywords
This publication has 37 references indexed in Scilit:
- ValidNESs: a database of validated leucine-rich nuclear export signalsNucleic Acids Research, 2012
- NESdb: a database of NES-containing CRM1 cargoesMolecular Biology of the Cell, 2012
- Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsLeukemia, 2012
- Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growthOncogene, 2012
- Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuliJournal of Cellular Physiology, 2011
- A Unique Metastasis Gene Signature Enables Prediction of Tumor Relapse in Early-Stage Hepatocellular Carcinoma PatientsCancer Research, 2010
- Recognition of nuclear targeting signals by Karyopherin-β proteinsCurrent Opinion in Structural Biology, 2010
- Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and TherapyAnnual Review of Medicine, 2010
- The mitochondrial p53 pathwayBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- Structural basis for leucine-rich nuclear export signal recognition by CRM1Nature, 2009